Weight loss revolution: noom teams up with GLP-1 drugs in massive new study
Disease control
Not yet recruiting
This study will test if combining GLP-1 medications (like semaglutide and tirzepatide) with Noom's digital health program helps people with obesity lose weight and improve health markers like blood sugar and cholesterol. About 2,310 adults will be followed for 24 months. The goal…
Sponsor: Noom Inc. • Aim: Disease control
Last updated May 26, 2026 09:51 UTC